Page last updated: 2024-11-06

o-desmethylangolensin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

o-Desmethylangolensin (o-DMA) is a naturally occurring phytoestrogen found in plants like clover, alfalfa, and soybeans. It is a derivative of the isoflavone daidzein, and its synthesis involves the removal of a methyl group from the daidzein molecule. o-DMA has been shown to exhibit estrogenic activity in both in vitro and in vivo studies. Its effects include modulation of hormone levels, potential antioxidant activity, and interactions with various cellular signaling pathways. While its biological role in humans is not fully understood, o-DMA is studied for its potential therapeutic applications, including its effects on bone health, cardiovascular health, and cancer prevention. Its presence in the diet and its interaction with the human body make it a subject of ongoing research.'
```

O-desmethylangolensin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID89472
CHEBI ID88902
SCHEMBL ID677731
SCHEMBL ID12255054
MeSH IDM0143149

Synonyms (23)

Synonym
o-desmethylangolensin
1-propanone, 1-(2,4-dihydroxyphenyl)-2-(4-hydroxyphenyl)-
o-demethylangolensin
21255-69-6
1-(2,4-dihydroxyphenyl)-2-(4-hydroxyphenyl)propan-1-one
scy1s10ok4 ,
unii-scy1s10ok4
SCHEMBL677731
SCHEMBL12255054
1-(2,4-dihydroxyphenyl)-2-(4-hydroxyphenyl)-1-propanone
o-demethylangolesin
2,4-dihydroxyphenyl p-hydroxyphenethyl ketone
AKOS028114536
o-demethylangolesin, 97% (cp)
CHEBI:88902
2',4'-dihydroxy-2-(p-hydroxyphenyl)-propiophenone
DTXSID40873154
Q27160940
desmethylangolensin
o-demethylangolensin; o-demethylangolesin
MS-23637
CS-0030650
HY-N4075

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic studies between SB and SAB showed modest differences."( Isoflavone pharmacokinetics and metabolism after consumption of a standardized soy and soy-almond bread in men with asymptomatic prostate cancer.
Ahn-Jarvis, JH; Clinton, SK; Cruz-Cano, R; Grainger, EM; Lee, ML; Lesinski, GB; Riedl, KM; Schwartz, SJ; Vodovotz, Y; Young, GS, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" The primary objective was to investigate isoflavone bioavailability and metabolite profile."( Isoflavone pharmacokinetics and metabolism after consumption of a standardized soy and soy-almond bread in men with asymptomatic prostate cancer.
Ahn-Jarvis, JH; Clinton, SK; Cruz-Cano, R; Grainger, EM; Lee, ML; Lesinski, GB; Riedl, KM; Schwartz, SJ; Vodovotz, Y; Young, GS, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
stilbenoidAny olefinic compound characterised by a 1,2-diphenylethylene backbone.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (50)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.00)18.7374
1990's5 (10.00)18.2507
2000's17 (34.00)29.6817
2010's24 (48.00)24.3611
2020's3 (6.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.59 (24.57)
Research Supply Index4.04 (2.92)
Research Growth Index5.33 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (9.80%)5.53%
Reviews3 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other43 (84.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]